2026 Cholesterol Guidelines, Explained in Plain English: What Changed, Who Needs Treatment, and What It Means for Real People

If you have ever been told your cholesterol is “a little high,” this new guideline matters to you.

In 2026, the American College of Cardiology and American Heart Association released a major update on how doctors should evaluate and treat dyslipidemia. That word includes more than just high LDL cholesterol. It now more clearly includes high triglycerides and elevated lipoprotein(a), also called Lp(a). The guideline officially retires and replaces the 2018 cholesterol guideline, and it expands the conversation from “cholesterol only” to a broader view of all the blood fats and particles that raise cardiovascular risk.

The big idea is simple: heart risk builds over time, and the earlier harmful particles are elevated, the more damage they can do. So the new guideline pushes clinicians to identify risk earlier, personalize treatment better, and use clearer treatment goals.

The biggest shift: this is no longer just a “cholesterol” guideline

One of the most important changes is conceptual. The document is no longer called a blood cholesterol guideline. It is now a guideline on the management of dyslipidemia. That matters because it recognizes that cardiovascular risk does not come only from LDL. Triglyceride-rich particles, remnant particles, and Lp(a) also matter. The guideline also folds in newer medicines and newer risk tools that were not part of the 2018 version.

In plain English, the new message is this:

Your doctor should not look only at one cholesterol number. They should look at your whole risk picture.

The top take-home messages, translated into normal language

The guideline’s own “Top Take-Home Messages” make the new priorities very clear.

First, it says treatment should start earlier in life when risk is building, especially in people with familial hypercholesterolemia, very high LDL, or a strong family history of early heart disease. Second, it replaces the older Pooled Cohort Equations with the newer PREVENT equations for estimating 10-year and 30-year risk in many adults. Third, it brings back clearer LDL and non-HDL treatment goals. Fourth, it elevates apoB and Lp(a) testing as more useful parts of risk assessment. Fifth, it gives a larger role to coronary artery calcium, or CAC, scanning for people in whom the decision is not obvious. It also tightens treatment goals in secondary prevention and emphasizes that statins remain the foundation for high triglycerides when the goal is reducing heart risk.

That is the executive summary. Now let’s break it down.

What is dyslipidemia?

Dyslipidemia means unhealthy levels of fats or fat-carrying particles in the blood. In this guideline, that includes elevated blood cholesterol, hypertriglyceridemia, and elevated Lp(a). It also reflects a broader understanding that atherosclerosis is driven by atherogenic lipoproteins, meaning particles that can get into artery walls and contribute to plaque buildup.

For most patients, the big players are:

LDL-C, often called “bad cholesterol”

non-HDL-C, which captures all the cholesterol carried by harmful particles, not just LDL

triglycerides, especially when elevated for long periods or very high

apoB, which is a count-like measure of the number of harmful particles

Lp(a), a genetically influenced particle that raises inherited heart risk

Why the guideline pushes earlier treatment

A major theme throughout the document is cumulative exposure. The longer your arteries are exposed to harmful lipoproteins, the more likely plaque is to build up. The guideline explicitly says clinicians should think about lifelong exposure, not just what is happening right now. It emphasizes starting health behavior counseling in youth and considering medication earlier in some young adults, particularly when LDL is high or family history is strong.

This is an important mindset change. A 35-year-old with “not terrible” numbers may still deserve serious attention if they have spent years accumulating risk.

The new risk calculator: PREVENT replaces the older PCE approach

One of the most important updates is the move to the AHA PREVENT equations instead of the older Pooled Cohort Equations for many adults in primary prevention. The guideline recommends using PREVENT in adults age 30 to 79 who do not already have ASCVD or known subclinical atherosclerosis and whose LDL is 70 to 189 mg/dL. It sorts people into these 10-year risk groups: low, less than 3%; borderline, 3% to less than 5%; intermediate, 5% to less than 10%; and high, 10% or greater.

The guideline describes a “CPR” approach:

Calculate risk

Personalize the estimate based on things the calculator misses

Reclassify if needed using tools like CAC scoring, then reassess treatment options

In plain English, the calculator is just the starting point. A good clinician is supposed to adjust the plan based on the person sitting in front of them.

LDL goals are back in a bigger way

One of the most practical changes is that the guideline does not rely only on “percent reduction” anymore. It brings back clear LDL-C and non-HDL-C goals. It still cares about percentage lowering, but now goals matter again.

For example, in primary prevention, patients at borderline or intermediate risk who start statins may be treated toward LDL-C under 100 mg/dL and non-HDL-C under 130 mg/dL. High-risk primary prevention patients may be treated toward LDL-C under 70 mg/dL and non-HDL-C under 100 mg/dL. In secondary prevention, many patients with established ASCVD, especially those at very high risk, now have a goal LDL-C under 55 mg/dL and non-HDL-C under 85 mg/dL.

This is a major practical shift because it gives patients and clinicians more concrete targets.

ApoB is no longer a niche test

The guideline gives apoB a much bigger role than many patients and even some clinicians may be used to.

ApoB is important because it reflects the number of harmful particles, not just how much cholesterol they carry. That distinction matters because some people have LDL-C that looks “at goal,” but they still have too many artery-clogging particles. The guideline says apoB can be reasonable in untreated adults to improve risk assessment, and especially useful in adults already on lipid-lowering therapy, particularly those with ASCVD, diabetes, CKM syndrome, or elevated triglycerides, to help decide whether treatment should be intensified after LDL and non-HDL goals are reached.

In plain English, apoB helps answer a question many standard lipid panels miss: “Are we really done treating this person, or is hidden residual risk still there?”

Lp(a) becomes mainstream: adults should have it checked at least once

This is one of the most important patient-facing changes in the whole guideline.

The new recommendation is that all adults should have Lp(a) measured at least once for risk assessment. The guideline also recommends cascade testing in first-degree relatives when there is familial hypercholesterolemia, premature ASCVD, or known high Lp(a).

Why? Because Lp(a) is largely genetic, mostly stable over time, and strongly tied to higher heart risk. The document notes that a level of 125 nmol/L, or 50 mg/dL, is considered high and is associated with roughly a 40% relative increase in ASCVD risk, while 250 nmol/L, or 100 mg/dL, is associated with about double the risk. On page 16, the guideline’s risk table shows that very high Lp(a) can raise risk to a degree similar to heterozygous familial hypercholesterolemia.

In real life, that means many people who think they have “normal cholesterol” may still carry inherited cardiovascular risk that has been invisible for years.

The guideline’s plain recommendation for people with elevated Lp(a) is not yet “take an Lp(a)-specific drug,” because those therapies are still evolving. Instead, it says to control all the other modifiable risk factors early and aggressively. In people with clinical ASCVD and high Lp(a) who have not reached LDL and non-HDL goals on statins, adding a PCSK9 monoclonal antibody is recommended.

Coronary calcium scoring gets a larger role

CAC scoring plays a much bigger role in the 2026 guideline than many people realize.

The document recommends using CAC when a patient is in an intermediate-risk group, or selected borderline-risk group, and the decision about treatment is still uncertain. It says CAC should be used to help decide whether to withhold, postpone, or start therapy. If CAC is zero and there are no higher-risk conditions, treatment can sometimes be deferred with repeat CAC in 3 to 7 years. But if CAC is above zero, especially 100 or more Agatston units or at or above the 75th percentile, lipid-lowering therapy is recommended.

The guideline also gives serious weight to incidental CAC found on non-cardiac CT scans. In other words, if calcium shows up on a lung scan or another chest CT, that should not be ignored. The presence of coronary atherosclerosis should be considered when making treatment decisions.

That is a major real-world update because many patients learn about plaque from scans that were never ordered to evaluate the heart.

Screening starts earlier and gets broader

The guideline recommends lipid screening in adults starting at age 19 and at least every 5 years after that, with more frequent screening for people with additional risk factors. In children age 9 to 11 who have not already been tested, it recommends a lipid profile to help detect familial hypercholesterolemia and other significant disorders. It also supports earlier cascade screening, starting as young as age 2, in children with a family history of premature ASCVD, severe hypercholesterolemia, or FH.

This is not just paperwork. It reflects the idea that silent, decades-long exposure matters.

Standard lipid testing changed in a subtle but important way

The guideline recommends a standard fasting or nonfasting lipid profile for most people. But it also updates how LDL should be estimated. It prefers the Martin/Hopkins or Sampson/NIH equations over the older Friedewald equation because they are more accurate, especially at low LDL or higher triglycerides. It also recommends routine reporting of non-HDL-C, and it explicitly says routine advanced lipoprotein subclass testing is not recommended for general risk assessment.

For patients, the translation is this: the lab math matters. The new guideline wants more accurate LDL estimates, especially when treatment decisions are close.

Lifestyle still matters, but the recommendations are sharper

The guideline strongly reinforces lifelong lifestyle management. It emphasizes healthy diet, regular exercise, healthy weight, good sleep, stress management, and avoiding tobacco. It treats these as core therapy, not optional extras.

For LDL problems, it recommends a diet centered on fruits, vegetables, nuts, legumes, whole grains, and fiber while replacing saturated and trans fats with monounsaturated and polyunsaturated fats. That means less butter, fatty red meat, and tropical oils, and more olive oil, nuts, seeds, fish, and plant-forward eating patterns.

For high triglycerides, the diet advice becomes more specific and more urgent. The guideline recommends cutting added sugar, refined carbohydrates, and saturated fat, minimizing or eliminating alcohol depending on triglyceride level, and using more intensive fat restriction in severe cases. It also emphasizes weight loss and physical activity. In highly responsive people, lifestyle change can lower triglycerides dramatically.

A major consumer-health takeaway: dietary supplements are not recommended for lipid lowering

This is one of the clearest “plain English” recommendations in the document.

The guideline says dietary supplements are not recommended to lower LDL or triglycerides because evidence is limited, inconsistent, or unimpressive. That includes many popular products marketed for “heart health.” It specifically notes that nonprescription fish oil products have not shown clinical benefit for patients with hypertriglyceridemia or ASCVD, and some may even increase LDL-C or atrial fibrillation risk. It also cites the SPORT trial, where rosuvastatin lowered LDL far more effectively than commonly used supplements, while the supplements did not significantly reduce LDL compared with placebo.

For normal people, the translation is blunt: supplements are not a substitute for proven therapy.

Registered dietitians get a bigger role

Another practical change is that the guideline becomes more explicit about when to refer to a registered dietitian nutritionist.

Referral is recommended for people with triglycerides at or above 1000 mg/dL because the dietary management becomes complex and pancreatitis risk becomes serious. Referral is also considered beneficial for people with triglycerides between 150 and 999 mg/dL who have features of CKM syndrome. The guideline notes that dietitian-led medical nutrition therapy can improve lipid levels and may even lower healthcare costs by reducing medication burden.

This matters because many patients are told to “eat better” without ever being given expert help.

Primary prevention: who should start treatment before having a heart event?

The new guideline is more willing to consider treatment earlier.

For adults at low risk under PREVENT, lifestyle is still the main recommendation, especially if LDL is below 160 mg/dL. But if LDL is 160 to 189 mg/dL, or 30-year risk is high in younger adults, moderate-intensity statin therapy becomes a reasonable option. In borderline risk patients, statins can be considered after a clinician-patient discussion. In intermediate risk patients, at least a moderate-intensity statin is recommended, and in the higher end of that risk range, a high-intensity statin can be beneficial. In high-risk primary prevention, high-intensity statin therapy is recommended, and ezetimibe can be added if goals are not reached.

This is more proactive than older “wait and see” mindsets.

Severe hypercholesterolemia and familial hypercholesterolemia get more aggressive treatment

Patients with LDL of 190 mg/dL or higher remain a special group, but the management is more detailed than before.

The guideline says standard general-population risk calculators should not be used for heterozygous familial hypercholesterolemia. It supports genetic testing in selected patients with severe hypercholesterolemia to help identify FH and better define risk. It also recommends adding nonstatin therapies such as ezetimibe, PCSK9 monoclonal antibodies, and/or bempedoic acid when maximally tolerated statins are not enough, with treatment goals depending on whether the patient has ASCVD, HeFH, or additional risk factors.

In the highest-risk severe hypercholesterolemia patients, inclisiran and even evinacumab enter the conversation.

Diabetes, CKD, HIV, cancer survivors, and pregnancy are given more explicit guidance

The guideline expands practical advice for several groups who often fall through the cracks.

For adults age 40 to 75 with diabetes and no ASCVD, statin therapy is indicated regardless of LDL level, with moderate intensity as baseline and high intensity for higher-risk individuals, along with LDL and non-HDL goals.

For adults with CKD stage 3 or higher and clinical ASCVD, the guideline recommends intensive LDL lowering to very low targets. For people living with HIV age 40 to 75 on stable antiretroviral therapy, statin therapy is recommended to reduce first ASCVD events and slow coronary plaque progression. Adult cancer survivors with at least two years of life expectancy should generally be treated similarly to people without a cancer history if they otherwise qualify for therapy. Pregnant patients with severe hypertriglyceridemia may, in selected cases, use fibrates after the first trimester or high-dose omega-3 ethyl esters as adjuncts to lifestyle management to reduce pancreatitis risk.

This is a more inclusive and more real-world guideline.

Secondary prevention: the LDL target is now much lower for many people

For patients who already have ASCVD, this guideline is tougher.

If a patient has clinical ASCVD and is not at very high risk, high-intensity statin therapy is still recommended, but the treatment goal is more concrete: LDL-C under 70 mg/dL and non-HDL-C under 100 mg/dL. If the patient is at very high risk, the goal becomes LDL-C under 55 mg/dL and non-HDL-C under 85 mg/dL, and the guideline recommends adding ezetimibe and/or a PCSK9 monoclonal antibody, with bempedoic acid and inclisiran as additional options in selected situations.

That is a clear message: after a heart attack, stroke, or other ASCVD event, the guideline wants LDL driven down harder than many patients saw in prior years.

Subclinical plaque now triggers more action

Patients with significant CAC, even without prior clinical ASCVD, are treated more seriously than before.

The guideline recommends therapy based on CAC burden. For CAC 100 to 299, or at or above the 75th percentile, treatment is recommended to reach LDL under 70 mg/dL and non-HDL under 100 mg/dL. For CAC 300 to 999, the same goals apply, and therapy intensification toward LDL under 55 mg/dL becomes reasonable. For CAC 1000 or more, the guideline recommends very aggressive LDL lowering with at least 50% reduction and a goal LDL under 55 mg/dL.

This is one reason CAC will likely become an even more powerful tool in preventive cardiology.

Hypertriglyceridemia: statins first for heart risk, other drugs for pancreatitis risk

The guideline treats triglycerides more carefully and more specifically than many older summaries did.

For severe hypertriglyceridemia, especially 500 mg/dL and above, treatment is aimed not just at heart risk but also at preventing pancreatitis. Statins remain first-line for ASCVD risk reduction, even though fibrates and prescription omega-3s may lower triglycerides more. The guideline notes that non-HDL-C and apoB are better treatment targets than LDL alone in many people with high triglycerides. It also says fibrates and niacin are not recommended as routine add-ons to statins for ASCVD event reduction, because outcomes data do not support that strategy. Icosapent ethyl is the key exception: it has cardiovascular outcomes evidence in appropriate high-risk patients on statins.

For familial chylomicronemia syndrome with very high triglycerides, the guideline recommends olezarsen as an adjunct to diet to lower triglycerides and reduce pancreatitis risk.

Statin muscle symptoms: the guideline tries to keep people on therapy, not give up too quickly

A lot of patients stop statins because of muscle symptoms. The 2026 guideline tackles this directly.

It says clinicians should evaluate for secondary causes, assess severity, and have an honest discussion about the cardiovascular risk of stopping therapy. In patients with ASCVD who have statin-attributed muscle symptoms and cannot reach goals, the guideline recommends using a lower tolerated statin dose if possible and adding nonstatin therapies such as ezetimibe, bempedoic acid, or PCSK9 monoclonal antibodies. In selected situations, inclisiran may also be reasonable.

It also lists factors that make muscle symptoms more likely, including older age, female sex, hypothyroidism, diabetes, liver disease, kidney disease, alcohol use, vigorous exercise, high-dose statins, interacting medications, and certain gene variants.

A helpful detail: the guideline says routine coenzyme Q10 is not recommended to treat or prevent statin muscle symptoms, and routine CK testing is not useful unless symptoms are severe.

Monitoring: don’t start therapy and then disappear

Once therapy starts, the guideline recommends a repeat lipid profile 4 to 12 weeks after starting or changing the dose, and then every 6 to 12 months after that to check effectiveness and adherence. The goal is not just to see whether the number moved, but whether the patient actually achieved the intended percentage reduction and absolute target.

That sounds basic, but it is one of the biggest reasons real-world care fails: treatment gets prescribed, but follow-up never really happens.

When should a patient see a lipid specialist?

The guideline says referral should be considered for people with suspected or diagnosed familial hypercholesterolemia, very early ASCVD, inability to hit targets despite maximally tolerated therapy, high Lp(a), severe hypertriglyceridemia, complex medication regimens such as HIV or cancer treatment, or pregnancy-related lipid management challenges.

That is important because lipid care is getting more specialized. The days of “just take a statin and we’re done” are fading.

What this guideline means for everyday patients

If you are a normal person trying to understand what to do with all this, here is the plain-English version.

If you have never had your Lp(a) checked, this guideline suggests you probably should at least once.

If your doctor still uses only total cholesterol and LDL without talking about risk, family history, triglycerides, apoB, or CAC when appropriate, the evaluation may be incomplete.

If you already have heart disease, the treatment goals are generally lower and more aggressive than many people realize.

If your triglycerides are high, the answer is not just “take fish oil.” Lifestyle, statins, and in selected cases prescription therapies matter more than over-the-counter supplements.

If you cannot tolerate a statin, that does not mean “do nothing.” The guideline offers several evidence-based backup options.

And if you are younger with strong family history or inherited lipid risk, waiting until age 55 is no longer the mindset this document encourages.

Conclusions On Treatment Guidelines For 2026

The 2026 dyslipidemia guideline is more aggressive, more personalized, and more practical than the 2018 version.

It expands the focus beyond LDL alone. It tells clinicians to measure risk earlier, check Lp(a) at least once, use PREVENT for risk estimation, use CAC more strategically, pay more attention to apoB, bring back LDL and non-HDL goals, treat established ASCVD to lower targets, and stop pretending that supplements are a substitute for evidence-based therapy.

Most of all, it reflects a simple truth: plaque builds quietly for years, so prevention has to start before the crisis.